• Dedicating to develop accessible drugs to benefit more patients
  Relationship research between pathogenic microorganisms and diseases
  Isolation and identification new functional strains
  Developing innovative microbiome-based drugs
• Based on R&D of Bacteroides fragilis, ZYBio has acquired the know-how from strains to LBP.
• 5 Major Milestones Leading the LBP Industry, with Advanced Clinical Progress:

SK08:

Phase III for IBS-D treatment

Phase I completed for UC treatment           

Phase I completed for pediatric acute diarrhea caused by rotavirus

Phase I in combination with PD-1 antibodies for advanced solid tumors

SK10:

Phase I completed under FDA for Chemotherapy-Induced Diarrhea (CID)